Literature DB >> 8086550

Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia.

J Ena1, C Amador, F Pasquau, C Carbonell, C Benito, F Gutiérrez, A Vilar.   

Abstract

We reviewed the charts of 52 patients infected with human immunodeficiency virus (HIV) who received at least three consecutive doses of intravenous pentamidine as prophylaxis for Pneumocystis carinii infections. Pentamidine isethionate was administered intravenously over 60-90 minutes once a month, at a dosage of 4 mg/kg, in 250 mL of 5% dextrose in water. During 387 months of administration of primary prophylaxis to 37 patients, no cases of P. carinii pneumonia were observed. During 200 months of administration of secondary prophylaxis to 15 patients, only one case of P. carinii pneumonia was diagnosed (6.0 cases per 100 patient-years). Side effects associated with the intravenous pentamidine were mild and did not necessitate withdrawal of the drug. Once-a-month administration of intravenous pentamidine is a valid alternative as prophylaxis for P. carinii pneumonia for patients who are intolerant of sulfonamides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086550     DOI: 10.1093/clinids/18.6.901

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

Review 1.  Prophylaxis against opportunistic infections in patients infected with the human immunodeficiency virus.

Authors:  L W Cheever; R E Chaisson; J E Gallant
Journal:  West J Med       Date:  1996 Jul-Aug

2.  IV pentamidine for Pneumocystis jiroveci pneumonia prophylaxis in pediatric allogeneic stem cell transplant patients.

Authors:  D A Curi; R E Duerst; C Badke; J Bell; S Chaudhury; M Kletzel; J Schneiderman; W T Tse; W J Muller; N Hijiya
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

3.  Visceral leishmaniasis in patients infected with the human immunodeficiency virus.

Authors:  F Laguna; M Adrados; J Alvar; V Soriano; M E Valencia; V Moreno; R Polo; J Verdejo; M I Jiménez; P Martínez; M L Martínez; J M González-Lahoz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-12       Impact factor: 3.267

Review 4.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy.

Authors:  Sadhna M Shankar; Joseph J Nania
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

6.  Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients.

Authors:  Su Young Kim; Alix A Dabb; Donald J Glenn; Kristen M Snyder; Meredith K Chuk; David M Loeb
Journal:  Pediatr Blood Cancer       Date:  2008-04       Impact factor: 3.167

7.  Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.

Authors:  Melissa Quinn; J T Fannin; Joseph Sciasci; Allison Bragg; Patrick K Campbell; Delia Carias; Kristine R Crews; David Gregornik; Sima Jeha; Gabriela Maron; Jennifer L Pauley; Hope D Swanson; Joshua Wolf; William Greene
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

Review 8.  Visceral Leishmaniasis and HIV coinfection in East Africa.

Authors:  Ermias Diro; Lutgarde Lynen; Koert Ritmeijer; Marleen Boelaert; Asrat Hailu; Johan van Griensven
Journal:  PLoS Negl Trop Dis       Date:  2014-06-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.